No attachments available.
Manufacturing of a Dissolving Microneedle Patch to Administer Rotavirus Vaccine
Contact and place of performance
Tim Williams
Atlanta, GA 30318
USA
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Centers for Disease Control and Prevention (CDC) National Center for Immunizations and Respiratory Diseases (NCIRD) intends to award a Firm Fixed Price Contract to Micron Biomedical Incorporated 311 FERST Drive NW STE L1309 Atlanta, Georgia 30318-5602. Under the authority of FAR 13.106-1(b)(1)(i) and 10U.S.C. 2...
View moreThe Centers for Disease Control and Prevention (CDC), National Center for Immunizations and Respiratory Diseases (NCIRD), intends to award a sole source, firm-fixed-price contract to Micron Biomedical Incorporated for the manufacturing of dissolving microneedle patches. This requirement supports the delivery of a live attenuated rotavirus vaccine intended for use in a future clinical trial. The project is classified under NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) and PSC B599 Special Studies/Analysis- Other.
Performance is scheduled to occur in Atlanta, Georgia, with an anticipated period of performance running from April 15, 2026, through April 14, 2028. The award is being pursued under the authority of FAR 13.106-1(b)(1)(i) and 10 U.S.C. 2304(c)(1), based on the determination that only one responsible source can satisfy the agency’s requirements. Tim Williams is the designated point of contact for this special notice, identified under solicitation number CDC-75D301-Presolicitation-MfgDMNPatch.
While this notice of intent is not a request for competitive proposals, interested sources may submit a capability statement for the government to consider in determining whether to conduct a competitive procurement. Submissions are limited to two pages and must include management, technical, and cost data demonstrating the ability to provide the required services and warranties. Capability statements must be submitted via email by 10:00 AM Eastern Standard Time on April 8, 2026, ahead of the anticipated award date on or before April 24, 2026.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.